These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 17080027)
21. Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma. Lanni TB; Greene KL; Kolz CN; Para KS; Visnick M; Mobley JL; Dudley DT; Baginski TJ; Liimatta MB Bioorg Med Chem Lett; 2007 Feb; 17(3):756-60. PubMed ID: 17095227 [TBL] [Abstract][Full Text] [Related]
22. The transforming functions of PI3-kinase-gamma are linked to disruption of intercellular adhesion and promotion of cancer cell invasion. Attoub S; De Wever O; Bruyneel E; Mareel M; Gespach C Ann N Y Acad Sci; 2008 Sep; 1138():204-13. PubMed ID: 18837901 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of PI3K and MEK: it is all about combinations and biomarkers. Rexer BN; Ghosh R; Arteaga CL Clin Cancer Res; 2009 Jul; 15(14):4518-20. PubMed ID: 19584146 [TBL] [Abstract][Full Text] [Related]
24. Altered heart rate and sinoatrial node function in mice lacking the cAMP regulator phosphoinositide 3-kinase-gamma. Rose RA; Kabir MG; Backx PH Circ Res; 2007 Dec; 101(12):1274-82. PubMed ID: 17975110 [TBL] [Abstract][Full Text] [Related]
25. Chemokines and chemokine receptors as therapeutic targets in lupus nephritis. Vielhauer V; Anders HJ; Schlöndorff D Semin Nephrol; 2007 Jan; 27(1):81-97. PubMed ID: 17336691 [TBL] [Abstract][Full Text] [Related]
33. Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice. Takeda M; Ito W; Tanabe M; Ueki S; Kato H; Kihara J; Tanigai T; Chiba T; Yamaguchi K; Kayaba H; Imai Y; Okuyama K; Ohno I; Sasaki T; Chihara J J Allergy Clin Immunol; 2009 Apr; 123(4):805-12. PubMed ID: 19232703 [TBL] [Abstract][Full Text] [Related]
34. [100 years of successful drug discovery. The history of aspirin]. Schrör K Pharm Unserer Zeit; 2009; 38(4):306-13. PubMed ID: 19572352 [No Abstract] [Full Text] [Related]
35. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation. Zhou HY; Shin EM; Guo LY; Youn UJ; Bae K; Kang SS; Zou LB; Kim YS Eur J Pharmacol; 2008 May; 586(1-3):340-9. PubMed ID: 18378223 [TBL] [Abstract][Full Text] [Related]
36. Chemokines and chemokine receptors in hematopoiesis and immunology. Broxmeyer HE Exp Hematol; 2006 Aug; 34(8):965-6. PubMed ID: 16863902 [No Abstract] [Full Text] [Related]
37. The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications. Weichhart T; Säemann MD Ann Rheum Dis; 2008 Dec; 67 Suppl 3():iii70-4. PubMed ID: 19022819 [TBL] [Abstract][Full Text] [Related]
38. Recent discovery of phosphoinositide 3-kinase γ inhibitors for the treatment of immune diseases and cancers. Qiu X; Tian Y; Liang Z; Sun Y; Li Z; Bian J Future Med Chem; 2019 Aug; 11(16):2151-2169. PubMed ID: 31538525 [TBL] [Abstract][Full Text] [Related]
39. Pursuing practical elegance in chemical synthesis. Noyori R Chem Commun (Camb); 2005 Apr; (14):1807-11. PubMed ID: 15795753 [TBL] [Abstract][Full Text] [Related]
40. Introduction to comments on 'Outsourcing: how to reform WHO for the 21st century'. Abimbola S BMJ Glob Health; 2016; 2(Suppl 1):i1. PubMed ID: 28609487 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]